Neurocrine’s Ingrezza shows improvement in tardive dyskinesia study

Neurocrine presented findings from a data analysis of KINECT-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia – TD – severity and awareness/distress and patient-reported TD impact. KINECT-4 is a Phase 3 study in which 163 participants with moderate to severe TD and underlying schizophrenia, schizoaffective disorder or mood disorder received 48 weeks of open-label treatment with once-daily Ingrezza followed by a four-week washout. The data was presented at the MDS International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. The data analysis evaluated the use of Ingrezza for the treatment of TD among all 167 patients with either schizophrenia or mood disorders enrolled over the course of the Phase 3, open-label, long-term study. On average, the analysis suggested that clinician-rated TD severity decreased with one-capsule, once-daily Ingrezza treatment over the course of the 48-week study. Researchers concluded that the use of AIMS and TDIS in evaluating symptom improvement during treatment may give a more complementary understanding regarding the patient’s TD experience.